197 related articles for article (PubMed ID: 35131860)
1. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer.
Maeda S; Motegi T; Iio A; Kaji K; Goto-Koshino Y; Eto S; Ikeda N; Nakagawa T; Nishimura R; Yonezawa T; Momoi Y
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131860
[TBL] [Abstract][Full Text] [Related]
2. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer.
Maeda S; Murakami K; Inoue A; Yonezawa T; Matsuki N
Cancer Immunol Res; 2019 Jul; 7(7):1175-1187. PubMed ID: 31160277
[TBL] [Abstract][Full Text] [Related]
3. Foxp3
Maeda S; Nakazawa M; Uchida M; Yoshitake R; Nakagawa T; Nishimura R; Miyamoto R; Bonkobara M; Yonezawa T; Momoi Y
Vet Pathol; 2020 Jul; 57(4):497-506. PubMed ID: 32347186
[TBL] [Abstract][Full Text] [Related]
4. Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.
Watanabe M; Kanao K; Suzuki S; Muramatsu H; Morinaga S; Kajikawa K; Kobayashi I; Nishikawa G; Kato Y; Zennami K; Nakamura K; Tsuzuki T; Yoshikawa K; Ueda R; Sumitomo M
Prostate; 2019 Oct; 79(14):1658-1665. PubMed ID: 31390096
[TBL] [Abstract][Full Text] [Related]
5. FOXP3/HAT1 Axis Controls Treg Infiltration in the Tumor Microenvironment by Inducing CCR4 Expression in Breast Cancer.
Sarkar T; Dhar S; Chakraborty D; Pati S; Bose S; Panda AK; Basak U; Chakraborty S; Mukherjee S; Guin A; Jana K; Sarkar DK; Sa G
Front Immunol; 2022; 13():740588. PubMed ID: 35222362
[TBL] [Abstract][Full Text] [Related]
6. BRAF
Maeda S; Yoshitake R; Chambers JK; Uchida K; Eto S; Ikeda N; Nakagawa T; Nishimura R; Goto-Koshino Y; Yonezawa T; Momoi Y
Vet Pathol; 2021 Sep; 58(5):971-980. PubMed ID: 33205710
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
[TBL] [Abstract][Full Text] [Related]
8. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
9. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
10. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
Doi T; Muro K; Ishii H; Kato T; Tsushima T; Takenoyama M; Oizumi S; Gemmoto K; Suna H; Enokitani K; Kawakami T; Nishikawa H; Yamamoto N
Clin Cancer Res; 2019 Nov; 25(22):6614-6622. PubMed ID: 31455681
[TBL] [Abstract][Full Text] [Related]
12. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
Remer M; Al-Shamkhani A; Glennie M; Johnson P
Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
[TBL] [Abstract][Full Text] [Related]
13. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
14. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
[TBL] [Abstract][Full Text] [Related]
15. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
16. Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer.
Ju M; Fan J; Zou Y; Yu M; Jiang L; Wei Q; Bi J; Hu B; Guan Q; Song X; Dong M; Wang L; Yu L; Wang Y; Kang H; Xin W; Zhao L
Front Immunol; 2022; 13():807840. PubMed ID: 35812443
[TBL] [Abstract][Full Text] [Related]
17. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.
Pere H; Montier Y; Bayry J; Quintin-Colonna F; Merillon N; Dransart E; Badoual C; Gey A; Ravel P; Marcheteau E; Batteux F; Sandoval F; Adotevi O; Chiu C; Garcia S; Tanchot C; Lone YC; Ferreira LC; Nelson BH; Hanahan D; Fridman WH; Johannes L; Tartour E
Blood; 2011 Nov; 118(18):4853-62. PubMed ID: 21908423
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.
Saito T; Kurose K; Kojima T; Funakoshi T; Sato E; Nishikawa H; Nakajima J; Seto Y; Kakimi K; Iida S; Doki Y; Oka M; Ueda R; Wada H
Nagoya J Med Sci; 2021 Nov; 83(4):827-840. PubMed ID: 34916725
[TBL] [Abstract][Full Text] [Related]
19. Depletion of central memory CD8
Maeda Y; Wada H; Sugiyama D; Saito T; Irie T; Itahashi K; Minoura K; Suzuki S; Kojima T; Kakimi K; Nakajima J; Funakoshi T; Iida S; Oka M; Shimamura T; Doi T; Doki Y; Nakayama E; Ueda R; Nishikawa H
Nat Commun; 2021 Dec; 12(1):7280. PubMed ID: 34907192
[TBL] [Abstract][Full Text] [Related]
20. Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis.
Hagemann UB; Gunnarsson L; Géraudie S; Scheffler U; Griep RA; Reiersen H; Duncan AR; Kiprijanov SM
PLoS One; 2014; 9(7):e103776. PubMed ID: 25080123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
